Jeffrey Hung

Mark Breidenbach

Michael Schmidt

Michael Yee

Swapnil Malekar

Yaron Werber

- Immuneering Corporation announced the closing of a private placement, generating **approximately $25 million** in total up front gross proceeds.  **[1790340_522de32cd0e44b8c8014201439e71bd3_0]** 
- The placement involved the sale of **6,329,113** unregistered shares of Class A common stock (or pre-funded warrants) at a purchase price of **$3.95 per share**.  **[1790340_522de32cd0e44b8c8014201439e71bd3_0]** 
- Accompanying purchase warrants to acquire **2,848,096** shares of Class A common stock were also issued, with an exercise price of **$5.50 per share**.  **[1790340_522de32cd0e44b8c8014201439e71bd3_0]** 
- Immuneering is a **clinical-stage oncology company** focused on developing Deep Cyclic Inhibitors for cancer treatment.  **[1790340_522de32cd0e44b8c8014201439e71bd3_1]**

Immuneering (IMRX)